Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate

Andrzej S. Januszewski, Hayden K. Young, Kwok Leung Ong, Liping Li, Rachel O’Connell, Timothy J. Lyons, C. Kelly, Dessi P. Zaharieva, David Sullivan, Russell Scott, Anthony Keech, Alicia J. Jenkins, the Field Study InvestigatorsJournal of Diabetes Investigation 2024 · DOI

Abstract

In type 2 diabetes, Hp levels differ by Hp phenotype and are decreased by fenofibrate in all phenotypes, but the effect is diminished in Hp 2-2.
BibTeX
@article{januszewski2024haptoglobin,
  author = {Andrzej S. Januszewski and Hayden K. Young and Kwok Leung Ong and Liping Li and Rachel O’Connell and Timothy J. Lyons and C. Kelly and Dessi P. Zaharieva and David Sullivan and Russell Scott and Anthony Keech and Alicia J. Jenkins and the FIELD Study Investigators},
  title = {{Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate}},
  journal = {Journal of Diabetes Investigation},
  year = {2024},
  doi = {10.1111/jdi.14290},
}

Loading related content...

Figure